Your browser doesn't support javascript.
loading
Emerging Therapies for Huntington's Disease - Focus on N-Terminal Huntingtin and Huntingtin Exon 1.
van der Bent, M Leontien; Evers, Melvin M; Vallès, Astrid.
Afiliación
  • van der Bent ML; uniQure biopharma B.V., Department of Research and Development, Amsterdam, the Netherlands.
  • Evers MM; uniQure biopharma B.V., Department of Research and Development, Amsterdam, the Netherlands.
  • Vallès A; uniQure biopharma B.V., Department of Research and Development, Amsterdam, the Netherlands.
Biologics ; 16: 141-160, 2022.
Article en En | MEDLINE | ID: mdl-36213816
Huntington's disease is a devastating heritable neurodegenerative disorder that is caused by the presence of a trinucleotide CAG repeat expansion in the Huntingtin gene, leading to a polyglutamine tract in the protein. Various mechanisms lead to the production of N-terminal Huntingtin protein fragments, which are reportedly more toxic than the full-length protein. In this review, we summarize the current knowledge on the production and toxicity of N-terminal Huntingtin protein fragments. Further, we expand on various therapeutic strategies targeting N-terminal Huntingtin on the protein, RNA and DNA level. Finally, we compare the therapeutic approaches that are clinically most advanced, including those that do not target N-terminal Huntingtin, discussing differences in mode of action and translational applicability.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Biologics Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Biologics Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos